NCI puts forward an annual plan and budget proposal that highlights the impact of the nation’s investment in cancer research and directs attention to several areas for which additional support will enable more progress. The stories of investigators found in this document illustrate the innovative research catalyzed by NCI-support, and the stories of patients and cancer survivors highlight how NCI’s investments in research help people live healthier lives.
We work with FDA's oncology (cancer) medical staff to bring your perspective into the review of new drugs to treat or prevent cancer. We also meet with organized patient advocacy groups to hear their concerns about drug development and to assist them in understanding the FDA drug regulatory process.
You and your loved ones can contact the Office of Health and Constituent Affairs with questions about cancer clinical trials or cancer drug development.
Norman Sharpless sworn in as director of the National Cancer Institute
Norman E. “Ned” Sharpless, M.D., took the oath of office late Tuesday, October 17, 2017, to become the 15th director of the National Cancer Institute (NCI), part of the National Institutes of Health. He succeeds Harold E. Varmus, M.D., who stepped down as director in March 2015. Douglas R. Lowy, M.D., has been NCI’s acting director since April 2015.
“It is an honor to welcome Dr. Sharpless to the Department of Health and Human Services and the National Institutes of Health,” said Acting Health and Human Services Secretary Eric D. Hargan. “We are grateful to Dr. Lowy for his service as acting director, and we look forward to Dr. Sharpless playing an integral role in this administration’s aggressive efforts to advance cancer research and cures for cancer patients.” More information